Pharmaceutical compositions of the isolated d-enantiomer of the quinazolinone derivative halofuginone
OwnerMordechai Erez, Karin Haleviinventors
Life of this patent
Estimating the term…
Abstract
The present invention relates to pharmaceutical compositions comprising as an active ingredient an isolated, chirally pure D-enantiomer of the quinazolinone derivative halofuginone having increased therapeutic activity and decreased side effects compared to the corresponding racemic mixtures, the composition being substantially free of the L-enantiomer and useful in the treatment of diseases and disorders associated with fibrotic conditions or cell proliferation.
Claims41
A pharmaceutical composition for the treatment of diseases and disorders associated with fibrotic conditions or cell proliferation, the composition comprising as an active ingredient an isolated quinazolinone derivative having the general formula (Ia):
- having the (2″R,3″S)trans configuration and being essentially free of the (2″S,3″R)trans enantiomer, wherein:
- n=1-2,
- R1 is at each occurrence independently selected from the group consisting of hydrogen, halogen, nitro, lower alkyl, phenyl and lower alkoxy;
- R2 is a member of the group consisting of hydroxy, acetoxy and lower alkoxy;
- and R3 is a member of the group consisting of hydrogen and lower alkenoxy-carbonyl, and pharmaceutically acceptable salts thereof, further comprising a pharmaceutically acceptable carrier or diluent, the quinazolinone derivative being at least 95% chirally pure (2″R,3″S)trans enantiomer.
A method of treating a disease or disorder associated with fibrotic conditions or cell proliferation, comprising administering to a subject in need thereof a pharmaceutical composition comprising as an active ingredient a therapeutically effective amount of an isolated quinazolinone derivative having the general formula (Ia):
- having the (2″R,3″S)trans configuration and being essentially free of the (2″S,3″R)trans enantiomer, wherein:
- n=1-2,
- R1 is at each occurrence independently selected from the group consisting of hydrogen, halogen, nitro, lower alkyl, phenyl and lower alkoxy;
- R2 is a member of the group consisting of hydroxy, acetoxy and lower alkoxy;
- and R3 is a member of the group consisting of hydrogen and lower alkenoxy-carbonyl, and pharmaceutically acceptable salts thereof, and a pharmaceutically acceptable carrier or diluent, the composition comprising at least 95% chirally pure (2″R,3″S)trans enantiomer of the quinazolinone derivative.
Dependencies are inferred from the claim text.